Elena Pegoraro

Prof. Elena Pegoraro

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
EPElena Pegoraro
Elena Pegoraro
Eric P HoffmanEric P Hoffman
Eric P Hoffman
LPL. Piva
L. Piva
BGB.F. Gavassini
B.F. Gavassini
SCStefano Cagnin
Stefano Cagnin
CMCraig M. McDonald
Craig M. McDonald
Objective: Duchenne muscular dystrophy (DMD) is the most common single-gene lethal disorder. Substantial patient–patient variability in disease onset and progression and response to glucocorticoids is seen, suggesting genetic or environmental modifiers. Methods: Two DMD cohorts were used as test and validation groups to define genetic modifiers: a Padova longitudinal cohort (n = 106) and the Cooperative International Neuromuscular Research Group (CINRG) cross-sectional natural history cohort (n = 156). Single nucleotide polymorphisms to be genotyped were selected from mRNA profiling in patients with severe vs mild DMD, and genome-wide association studies in metabolism and polymorphisms influencing muscle phenotypes in normal volunteers were studied. Results: Effects on both disease progression and response to glucocorticoids were observed with polymorphism rs28357094 in the gene promoter of SPP1 (osteopontin). The G allele (dominant model; 35% of subjects) was associated with more rapid progression (Padova cohort log rank p = 0.003), and 12%–19% less grip strength (CINRG cohort p = 0.0003). Conclusions: Osteopontin genotype is a genetic modifier of disease severity in Duchenne dystrophy. Inclusion of genotype data as a covariate or in inclusion criteria in DMD clinical trials would reduce intersubject variance, and increase sensitivity of the trials, particularly in older subjects.

1 March 2014 in Neuromuscular Disorders
Verified
Journal Article
Open access
MPMarika Pane
Marika Pane
EMElena S. Mazzone
Elena S. Mazzone
LFLavinia Fanelli
Lavinia Fanelli
RSRoberto De Sanctis
Roberto De Sanctis
FBFlaviana Bianco
Flaviana Bianco
EMEugenio Mercuri
Eugenio Mercuri
The Performance of Upper Limb was specifically designed to assess upper limb function in Duchenne muscular dystrophy. The aim of this study was to assess (1) a cohort of typically developing children from the age of 3years onwards in order to identify the age when the activities assessed in the individual items are consistently achieved, and (2) a cohort of 322 Duchenne children and young adults to establish the range of findings at different ages. We collected normative data for the scale validation on 277 typically developing subjects from 3 to 25years old. A full score was consistently achieved by the age of 5years. In the Duchenne cohort there was early involvement of the proximal muscles and a proximal to distal progressive involvement. The scale was capable of measuring small distal movements, related to activities of daily living, even in the oldest and weakest patients. Our data suggest that the assessment can be reliably used in both ambulant and non ambulant Duchenne patients in a multicentric setting and could therefore be considered as an outcome measure for future trials.

1 December 2005 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
CBChiara A. Boito
Chiara A. Boito
PMPaola Melacini
Paola Melacini
Andrea VianelloAndrea Vianello
Andrea Vianello
PPPaola Prandini
Paola Prandini
BGBruno F. Gavassini
Bruno F. Gavassini
EPElena Pegoraro
Elena Pegoraro
Limb-girdle muscular dystrophy type 2I (LGMD2I) is an autosomal recessive muscular dystrophy caused by mutations in the FKRP gene.1FKRP encodes a putative Golgi-resident glycosyltransferase fukutin-related protein that is involved in α-dystroglycan glycosylation.1,2 Missense, nonsense, and insertion and deletion mutations have been reported in the 1.5-kilobase (kb) coding exon of FKRP in large series of patients with limb-girdle muscular dystrophies.1,3-8 Most of the FKRP mutations are rare, but the 826C>A mutation is common.1,3,4,6,7,9 The clinical phenotype in LGMD2I is heterogeneous, including asymptomatic FKRP mutation carriers,6 patients with a severe early-onset type of Duchenne muscular dystrophy, and patients with mild late-onset muscular dystrophy with slow progression. Dilated cardiomyopathy and severe restrictive respiratory insufficiency have been reported in several, but not all, patients with LGMD2I.1,3-7,10 The emerging pattern of muscle involvement in LGMD2I includes proximal distribution of weakness in the limbs, with the hips more affected than the shoulders.3 Muscle hypertrophy is common, including the calves and, occasionally, other muscles. FKRP mutations have also been reported in a severe form of congenital muscular dystrophy (MDC1C)11 and in congenital muscular dystrophy complicated by structural brain abnormalities (a complete list of FKRP mutations is available at: http://www.dmd.nl).

Verified
Journal Article
Open access
PDF file
LBLuca Bello
Luca Bello
EPElena Pegoraro
Elena Pegoraro
Duchenne muscular dystrophy (DMD), the most severe form of dystrophinopathy, is quite homogeneous with regards to its causative biochemical defect, i.e., complete dystrophin deficiency, but not so much with regards to its phenotype. For instance, muscle weakness progresses to the loss of independent ambulation at a variable age, starting from before 10 years, to even after 16 years (with glucocorticoid treatment). Identifying the bases of such variability is relevant for patient counseling, prognosis, stratification in trials, and identification of therapeutic targets. To date, variants in five loci have been associated with variability in human DMD sub-phenotypes: SPP1, LTBP4, CD40, ACTN3, and THBS1. Four of these genes (SPP1, LTBP4, CD40, and THBS1) are implicated in several interconnected molecular pathways regulating inflammatory response to muscle damage, regeneration, and fibrosis; while ACTN3 is known as “the gene for speed”, as it contains a common truncating polymorphism (18% of the general population), which reduces muscle power and sprint performance. Studies leading to the identification of these modifiers were mostly based on a “candidate gene” approach, hence the identification of modifiers in “usual suspect” pathways, which are already known to modify muscle in disease or health. Unbiased approaches that are based on genome mapping have so far been applied only initially, but they will probably represent the focus of future developments in this field, and will hopefully identify novel, “unsuspected” therapeutic targets. In this article, we summarize the state of the art of modifier loci of human dystrophin deficiency, and attempt to assess their relevance and implications on both clinical management and translational research.

10 July 2012 in Neurology
Verified
Journal Article
Closed access
PDF file
LBLuca Bello
Luca Bello
LPLuisa Piva
Luisa Piva
ABAndrea Barp
Andrea Barp
ATAntonella Taglia
Antonella Taglia
EPEsther Picillo
Esther Picillo
EPElena Pegoraro
Elena Pegoraro
Objective: To test the effect of the single nucleotide polymorphism −66 T>G (rs28357094) in the osteopontin gene (SPP1) on functional measures over 12 months in Duchenne muscular dystrophy (DMD). Methods: This study was conducted on a cohort of ambulatory patients with DMD from a network of Italian neuromuscular centers, evaluated longitudinally with the North Star Ambulatory Assessment (NSAA) and the 6-Minute Walk Test (6MWT) at study entry and after 12 months. Genotype at rs28357094 was determined after completion of the clinical evaluations. Patients were stratified in 2 groups according to a dominant model (TT homozygotes vs TG heterozygotes and GG homozygotes) and clinical data were retrospectively compared between groups. Results: Eighty patients were selected (age 4.1–19.3 years; mean 8.3 ± 2.7 SD). There were no differences in age or steroid treatment between the 2 subgroups. Paired t test showed a significant difference in both NSAA (p = 0.013) and 6MWT (p = 0.03) between baseline and follow-up after 12 months in patients with DMD carrying the G allele. The difference was not significant in the T subgroup. The analysis of covariance using age and baseline values as covariate and SPP1 genotype as fixed effect showed that these parameters are significantly correlated with the 12-month values. Conclusions: These data provide evidence of the role of SPP1 genotype as a disease modifier in DMD and support its relevance in the selection of homogeneous groups of patients for future clinical trials.

28 April 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
CSClaudio Semplicini
Claudio Semplicini
JVJohn Vissing
John Vissing
JDJulia R. Dahlqvist
Julia R. Dahlqvist
TSTanya Stojkovic
Tanya Stojkovic
LBLuca Bello
Luca Bello
EPElena Pegoraro
Elena Pegoraro
Objective: To determine the clinical spectrum of limb-girdle muscular dystrophy 2E (LGMD2E) and to investigate whether genetic or biochemical features can predict the phenotype of the disease. Methods: All LGMD2E patients followed in participating centers were included. A specific clinical protocol was created, including quantitative evaluation of motor, respiratory, and cardiac function. Phenotype was defined as severe or mild if the age at loss of ambulation occurred before or after 18 years. Molecular analysis of SGCB gene and biochemical features of muscle biopsies were reviewed. Results: Thirty-two patients were included (16 male, 16 female; age 7–67 years; 15 severe, 12 mild, and 5 unknown). Neurologic examination showed proximal muscle weakness in all patients, but distal involvement was also observed in patients with severe disease early in the disease course. Cardiac involvement was observed in 20 patients (63%) even before overt muscle involvement. Six patients had restrictive respiratory insufficiency requiring assisted ventilation (19%). Seventeen different mutations were identified, and 3 were recurrent. The c.377_384dup (13 alleles) was associated with the severe form, the c.-22_10dup (10) with the milder form, and the c.341C>T (9) with both. The entire sarcoglycan complex was undetectable by muscle immunohistochemistry or Western blot in 9/10 severe cases and reduced in 7/7 mild cases. The residual amount of sarcoglycan in muscle resulted a predictor of age at loss of ambulation. Conclusions: This study expands the spectrum of phenotype in β-sarcoglycanopathy and provides strong evidence that severity of clinical involvement may be predicted by SGCB gene mutation and sarcoglycan protein expression.